Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-MAP3K7 Recombinant Antibody (A996) (CBMAB-AP11659LY)


See all MAP3K7 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
A996
Antibody Isotype
IgG
Application
IF, IP, WB

Basic Information

Immunogen
A synthetic Peptide of human MAP3K7
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
Affinity purity
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Mitogen-Activated Protein Kinase Kinase Kinase 7
Introduction
The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Entrez Gene ID
Human6885
Mouse26409
Rat313121
UniProt ID
HumanO43318
MouseQ62073
RatP0C8E4
Alternative Names
Mitogen-Activated Protein Kinase Kinase Kinase 7; Transforming Growth Factor-Beta-Activated Kinase 1; TGF-Beta Activated Kinase 1; EC 2.7.11.25; TAK1; TGF-Beta-Activated Kinase 1;
Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis (By similarity).
Biological Process
Activation of NF-kappaB-inducing kinase activityManual Assertion Based On ExperimentIMP:UniProtKB
AnoikisISS:BHF-UCL
Cytoplasmic pattern recognition receptor signaling pathwayTAS:Reactome
Fc-epsilon receptor signaling pathwayTAS:Reactome
Histone H3 acetylationManual Assertion Based On ExperimentIDA:BHF-UCL
I-kappaB kinase/NF-kappaB signalingTAS:Reactome
I-kappaB phosphorylationManual Assertion Based On ExperimentIDA:UniProtKB
Interleukin-1-mediated signaling pathwayTAS:Reactome
JNK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
MAPK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
MyD88-dependent toll-like receptor signaling pathwayTAS:Reactome
Nucleotide-binding oligomerization domain containing signaling pathwayTAS:Reactome
p38MAPK cascadeTAS:Reactome
Positive regulation of I-kappaB kinase/NF-kappaB signalingManual Assertion Based On ExperimentIMP:UniProtKB
Positive regulation of interleukin-2 productionManual Assertion Based On ExperimentIMP:UniProtKB
Positive regulation of JUN kinase activityManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of macroautophagyISS:BHF-UCL
Positive regulation of NF-kappaB transcription factor activityTAS:Reactome
Positive regulation of T cell cytokine productionManual Assertion Based On ExperimentIMP:UniProtKB
Stimulatory C-type lectin receptor signaling pathwayTAS:Reactome
Stress-activated MAPK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
T cell receptor signaling pathwayTAS:Reactome
Transforming growth factor beta receptor signaling pathwayManual Assertion Based On ExperimentTAS:ProtInc
Cellular Location
Cytoplasm
Cell membrane
Although the majority of MAP3K7/TAK1 is found in the cytosol, when complexed with TAB1/MAP3K7IP1 and TAB2/MAP3K7IP2, it is also localized at the cell membrane.
Involvement in disease
Frontometaphyseal dysplasia 2 (FMD2):
A form of frontometaphyseal dysplasia, a progressive sclerosing skeletal dysplasia affecting the long bones and skull. Characteristic features include supraorbital hyperostosis, cranial hyperostosis, undermodeling of the small bones, flared metaphyses, and digital anomalies. Extra-skeletal manifestations include hearing loss, cardiac malformations, and stenosis, particularly of the upper airway and urinary tract. FMD2 inheritance is autosomal dominant.
Cardiospondylocarpofacial syndrome (CSCF):
A syndrome characterized by growth retardation, dysmorphic facial features, brachydactyly with carpal-tarsal fusion and extensive posterior cervical vertebral synostosis, cardiac septal defects with valve dysplasia, and deafness with inner ear malformations. CSCF transmission pattern is consistent with autosomal dominant inheritance.
PTM
Association with TAB1/MAP3K7IP1 promotes autophosphorylation at Ser-192 and subsequent activation. Association with TAB2/MAP3K7IP2, itself associated with free unanchored Lys-63 polyubiquitin chain, promotes autophosphorylation and subsequent activation of MAP3K7. Dephosphorylation at Ser-192 by PPM1B/PP2CB and at Thr-187 by PP2A and PPP6C leads to inactivation.
'Lys-48'-linked polyubiquitination at Lys-72 is induced by TNFalpha, and leads to proteasomal degradation. Undergoes 'Lys-48'-linked polyubiquitination catalyzed by ITCH (By similarity).
Requires 'Lys-63'-linked polyubiquitination for autophosphorylation and subsequent activation. 'Lys-63'-linked ubiquitination does not lead to proteasomal degradation. Deubiquitinated by CYLD, a protease that selectively cleaves 'Lys-63'-linked ubiquitin chains. Deubiquitinated by Y.enterocolitica YopP.
(Microbial infection) Cleaved and inactivated by the proteases 3C of coxsackievirus A16 and human enterovirus D68, allowing the virus to disrupt TRAF6-triggered NF-kappa-B induction.
(Microbial infection) Acetylation of Thr-184 and Thr-187 by Yersinia YopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
More Infomation

Minatogawa, M., Miyake, N., Tsukahara, Y., Tanabe, Y., Uchiyama, T., Matsumoto, N., & Kosho, T. (2022). Expanding the phenotypic spectrum of cardiospondylocarpofacial syndrome: From a detailed clinical and radiological observation of a boy with a novel missense variant in MAP3K7. American Journal of Medical Genetics Part A, 188(1), 350-356.

van Woerden, G. M., Senden, R., de Konink, C., Trezza, R. A., Baban, A., Bassetti, J. A., ... & Demirdas, S. (2022). The MAP3K7 gene: Further delineation of clinical characteristics and genotype/phenotype correlations. Human mutation, 43(10), 1377-1395.

Zhang, J., Cao, L., Wang, X., Li, Q., Zhang, M., Cheng, C., ... & Zhang, Y. (2022). The E3 ubiquitin ligase TRIM31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of MAP3K7 in the TGF-β1 signaling pathway. Cell Death & Differentiation, 29(3), 556-567.

Jillson, L. K., Rider, L. C., Rodrigues, L. U., Romero, L., Karimpour-Fard, A., Nieto, C., ... & Cramer, S. D. (2021). MAP3K7 loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate cancer with joint loss of CHD1. Molecular Cancer Research, 19(7), 1123-1136.

Huang, Z., Tang, B., Yang, Y., Yang, Z., Shi, L., Bai, Y., ... & Huang, H. (2021). MAP3k7-ikk inflammatory signaling modulates ar protein degradation and prostate cancer progression. Cancer research, 81(17), 4471-4484.

Jin, X., Fu, W., Li, D., Wang, N., Chen, J., Zeng, Z., ... & Li, Y. (2021). High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7. OncoTargets and therapy, 1753-1769.

Shen, X., Kong, S., Yang, Q., Yin, Q., Cong, H., Wang, X., & Ju, S. (2020). PCAT‐1 promotes cell growth by sponging miR‐129 via MAP3K7/NF‐κB pathway in multiple myeloma. Journal of Cellular and Molecular Medicine, 24(6), 3492-3503.

Washino, S., Rider, L. C., Romero, L., Jillson, L. K., Affandi, T., Ohm, A. M., ... & Cramer, S. D. (2019). Loss of MAP3K7 sensitizes prostate cancer cells to CDK1/2 inhibition and DNA damage by disrupting homologous recombination. Molecular Cancer Research, 17(10), 1985-1998.

Cheng, J. S., Tsai, W. L., Liu, P. F., Goan, Y. G., Lin, C. W., Tseng, H. H., ... & Shu, C. W. (2019). The MAP3K7-mTOR axis promotes the proliferation and malignancy of hepatocellular carcinoma cells. Frontiers in Oncology, 9, 474.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAP3K7 Recombinant Antibody (A996)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry